Stay updated on Long-term Safety of Dupilumab in Pediatric AD Clinical Trial
Sign up to get notified when there's something new on the Long-term Safety of Dupilumab in Pediatric AD Clinical Trial page.

Latest updates to the Long-term Safety of Dupilumab in Pediatric AD Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedRevision: v3.6.4 is now shown, replacing the previous Revision: v3.6.3. This indicates a new page revision.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe page revision metadata was updated from v3.6.2 to v3.6.3, reflecting a newer version of the page.SummaryDifference0.0%

- Check37 days agoChange DetectedThe page's revision tag was updated to v3.6.2 and the older tag removed, indicating a backend update. It does not change the visible study content or user-facing information.SummaryDifference0.0%

- Check52 days agoChange DetectedNew help/navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study) and a recruitment note ('No longer looking for participants'), while the 'Intervention / Treatment' heading was replaced with 'Intervention/Treatment' and the 'Revision: v3.5.5' tag was removed.SummaryDifference0.2%

- Check59 days agoChange DetectedThe page now shows Revision: v3.5.5, replacing the previous Revision: v3.5.4. This indicates a minor software/content rendering update for the study page.SummaryDifference0.0%

- Check66 days agoChange DetectedA new publication citation about the safety and efficacy of dupilumab in infants and young children with atopic dermatitis was added to the Publications section, and an older online-ahead-of-print citation for the same topic was removed.SummaryDifference0.1%

Stay in the know with updates to Long-term Safety of Dupilumab in Pediatric AD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Long-term Safety of Dupilumab in Pediatric AD Clinical Trial page.